IFN-y (BSB-161), MMab

Description

IFN-γ is a dimerized soluble cytokine and the only member of the type II interferon. In humans, IFN-γ is encoded by the IFNG gene and is critical for innate and adaptive immunity against viral, some bacterial and protozoal infections. IFN-γ is produced predominantly by natural killer and natural killer T cells as part of the innate immune response, and by CD4 Th1 and CD8 cytotoxic T lymphocytes effector T cells once antigen-specific immunity develops as part of the adaptive immune response. IFN-γ is also produced by non-cytotoxic innate lymphoid cells. IFN-γ interacts with its receptors interferon gamma receptor 1 and interferon gamma receptor 2 and activates them. IFN-γ binding to the receptors activates the JAK-STAT pathway. IFN-γ also binds to the glycosaminoglycan heparan sulfate and inhibits its biological activity. IFN-γ is used to treat Chronic Granulomatous Disease and Osteopetrosis, also has potential as cancer immunotherapy to improve survival in Bladder Carcinoma, Melanoma, and Ovarian Carcinoma.

Caractéristiques

Type

Mouse Monoclonal

Clone

BSB-161

Isotype

IgG2a

Réactivité

Paraffin, Frozen

Localisation

Cytoplasmic, Membranous

Contrôle

Stomach, Fallopian Tube, Colon, Lung Adenocarcinoma, Ductal Breast Carcinoma, Pancreatic Adenocarcinoma

Usage prévu

For In Vitro Diagnostic Use